NCT07559084Not yet recruiting
Multi-target TMS for Schizophrenia Negative Symptoms
Development of a Multi-target Transcranial Magnetic Intervention Technique for Negative Symptoms of Schizophrenia
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 9 Apr 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Shanghai Mental Health Center
- Diseases
- Schizophrenia
- NCT number
- NCT07559084
What you commit to
- Study type: Interventional
- Planned participants: 64
- From 1 Oct 2026 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcohol abuse within 30 days prior to the study or alcohol/drug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline;
Other illness
- Current or lifetime psychiatric disorders as determined by SCID-5 assessment;
- Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions;
- No history of modified electroconvulsive therapy (mECT) within the past 6 months.
Other
- Pregnant or breastfeeding women;
- Intellectual disability (IQ \< 70);
Who the study is looking for
- Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center;
- Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment;
- Male or female aged 16-45 years;
- Education duration ≥ 9 years;
- Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit;
- Participants and their guardians can understand and sign written informed consent;
- Total score on the PANSS Negative Symptom subscale (PANSS-N) \> 15, and at least one item score ≥ 3.
Age in the registry: 16 years to 45 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Mental Health Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.